Covariate | Before propensity match score | After propensity match score | |||
---|---|---|---|---|---|
 | Group G n = 662 | Group E n = 264 | P valve | Group G n = 264 | P valve |
Age | 58.32 ± 12.703 | 56.62 ± 13.809 | 0.073 | 58.54 ± 11.968 | 0.088 |
Height | 165.45 ± 6.903 | 165.945 ± 7.090 | 0.329 | 165.417 ± 7.102 | 0.393 |
Weight | 63.66 ± 10.144 | 63.364 ± 10.608 | 0.693 | 63.520 ± 10.706 | 0.866 |
Gender | Â | Â | 0.076 | Â | 0.170 |
 male | 571 (83.6%) | 239 (90.5%) |  | 229 (86.7%) |  |
 female | 91 (13.7%) | 25 (9.5%) |  | 35 (13.3%) |  |
Hypertension | Â | Â | 0.095 | Â | 0.662 |
 yes | 159 (24.0%) | 50 (18.9%) |  | 54 (20.5%) |  |
 no | 503 (76.0%) | 214 (81.1%) |  | 210 (79.5%) |  |
Diabetes mellitus | Â | Â | 0.495 | Â | 0.579 |
 yes | 43 (6.5%) | 14 (5.3%) |  | 17 (6.4%) |  |
 no | 619 (93.5%) | 250 (94.7%) |  | 247 (93.6%) |  |
TNM stage | Â | Â | 0.697 | Â | 0.609 |
 TaN0M0 | 507 (76.6%) | 199 (74.5%) |  | 204 (77.3%) |  |
 T1N0M0 | 155 (23.4%) | 65 (24.6%) |  | 60 (22.7%) |  |
Grade | Â | Â | 0.060 | Â | 0.226 |
 Low malignant potential | 155 (23.4%) | 74 (28.0%) |  | 63 (23.9%) |  |
 Low-grade papillary urothelial carcinoma | 291 (44.0%) | 124 (47.0%) |  | 118 (44.7%) |  |
 High-grade papillary urothelial carcinoma | 216 (32.6%) | 66 (25.0%) |  | 83 (31.4%) |  |
Tumour size | Â | Â | 0.169 | Â | 0.786 |
 < 3 cm | 450 (68.0%) | 167 (63.3%) |  | 170 (64.4%) |  |
 ≥ 3 cm | 212 (32.0%) | 97 (36.7%) |  | 74 (35.6%) |  |
Number of tumour | Â | Â | 0.150 | Â | 0.207 |
 Solitary | 432 (65.3%) | 159 (60.2%) |  | 173 (65,5%) |  |
 Multiple | 230 (34.7%) | 105 (39.8%) |  | 91 (34.5%) |  |
Risk group | Â | Â | 0.163 | Â | 0.500 |
 High-risk tumour | 267 (40.3%) | 92 (34.8%) |  | 105 (39.8%) |  |
 Intermediate-risk tumour | 187 (28.2%) | 90 (34.1%) |  | 82 (31.1%) |  |
 Low-risk tumour | 208 (31.4%) | 82 (31.1%) |  | 77 (29.2%) |  |
Intravesical chemotherapy | Â | Â | 0.976 | Â | 0.595 |
 yes | 264 (39.9%) | 105 (39.8%) |  | 111 (42.0%) |  |
 no | 398 (60.1%) | 159 (60.2%) |  | 153 (58.0%) |  |